Clinical and Pathological Response to Neoadjuvant Anthracycline Based Chemotherapy in women with breast cancer

Abstract

BackgroundNeoadjuvant chemotherapy has been used as a primary treatment for locally advanced or inflammatory breast cancer, and recently extended to operable breast cancer. The aim of this study was to evaluate the predictive value of different histologic factors in breast cancer treated with neoadjuvant anthracycline chemotherapy in Tunisian women.MethodsA total of 109 stage II and III breast cancer patients who received neoadjuvant anthracycline chemotherapy were enrolled in this study. Using pretreatment biopsy materials, histologic grade was recorded and immunohistochemical studies were performed for estrogen receptor, progesterone receptor and Her2neu. We analyzed the associations among this histologic factors and clinical and pathological complete response. Statistical analysis used is SEM logiciel.ResultsThe overall clinical response was 63% (clinical partial response in 49% of cases and clinical complete response in 14% of cases). The pCR was 7%; in univariate analysis, clinical response rate by each factors were as follows: 63% in ER-positive tumors, 84% in ER-negative (P = 0.2), 59% in PgR-positive, 62% in PgR-negative (P = 0.3), 64% in HER2-positive, 62% in HER2-negative (P = 0.6), 60% in tumors of low nuclear grade and 63% in ones of high nuclear grade (P = 0.9).ConclusionsBiological markers that reliably predict clinical and pathological response to primary systemic therapy may have considerable clinical potential. The future of neoadjuvant therapy lies in tailoring treatment to individual patients by identifying response predictors.

<p>A Study on Clinical and Pathological Responses to Neoadjuvant Chemotherapy in Breast Carcinoma</p>

“…While comparing with another study, complete clinical response in our study (26.6%) was comparable with Alvarado et al, 19 which showed a cCR of 12%, and Garbhi olfa et al, 20 which showed a cCR of 14%. The partial response rate in our study was 50%.…”

Pathological Patterns and Complete Response Rates after Neoadjuvant Chemotherapy and Chemoradiation in Locally Advanced Breast Cancer- an audit of 104 Patients

“…In this study we have analysed the incidence of pCR to neoadjuvant chemotherapy and chemoradiation in our patient population. In various studies, incidence of pCR ranges from 12-30% in anthracycline based therapy [6]. The pCR rate in this study (14.4%) is comparable to other published series using anthracycline based chemotherapy [6,7,8] .…”

“…In various studies, incidence of pCR ranges from 12-30% in anthracycline based therapy [6]. The pCR rate in this study (14.4%) is comparable to other published series using anthracycline based chemotherapy [6,7,8] . In a study by Prisack et al [9] pCR was seen more frequent in tumors that received radiochemotherapy (28.3%) compared to chemotherapy alone (11.9%).We also noticed a higher pCR in neoadjuvant chemoradiation (23%) though the sample size is not comparable.…”

Evaluation of morphological predictors for response to NACT in breast cancer

“…Pathological complete response is one of the important predicting long time survival in Post NACT patients. The pathological complete response rates varied from 8-30% in various anthracycline based regimens (8)(9)(10)(11)(12) . In the present study the pathological complete response was observed in 42 out of 108 cases constituting 39%.we did find one study with a higher pathological complete response of 40%.…”